Drug news
Cel-Sci Corpn to commence Phase III trial of MultiKine in Head and Neck Cancer
Phase III study to commence for MultiKine from Cel-SciCorpn. in third quarter of 2010 being the largest Head and Neck Cancer trial ever. MultiKine,cancer immunotherapy ,is being given to treatment naive patients before surgery/radiation or chemotherapy as it is best to stimulate an anti tumour immune response while the immune system is still competent. Cel-Sci are partnered with Teva Pharma and Orient Europharma. MultiKine is considered the first in a new class of immune simulators.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.